
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical is a surgical aesthetics provider leveraging its unique helium plasma technology to develop and market a range of cosmetic and surgical products and technologies. With its upcoming launch of the AYON Body Contouring System, anticipated label expansion for power liposuction, and a strong financial position, it is well-positioned to capitalize on the growing demand for skin tightening and body contouring treatments, particularly among GLP-1 users. The company's recent strategic initiatives, including cost reduction and streamlining of operations, also add to its positive outlook, with expectations of sustainable adj. EBITDA profitability.
Bears say
Apyx Medical is benefiting from the strong commercial adoption of its newly launched AYON Body Contouring System, which has generated strong early demand and positive surgeon feedback, while also pairing synergistically with the company's Renuvion technology. The company's strategic rebranding to Surgical Aesthetics, leaner cost structure, expanding U.S. sales, improved gross margins, and reduced losses and cash burn also support a positive outlook. However, potential risks include regulatory setbacks, slower commercialization of AYON, economic factors affecting the aesthetics market, and competitive threats.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares